Andrew S. Bomback, MD
Appointments
Phone Appointments
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Credentials & Experience
Board Certifications
- Nephrology
- Internal Medicine
Clinical Expertise
- Chronic Glomerular Diseases
- Glomerular Diseases and Nephrotic Syndrome
- Glomerulonephritis
Specialties
Education & Training
- Columbia University College of Physicians and Surgeons
- Residency: University of North Carolina Hospital
- Fellowship: University of North Carolina Hospital
About Andrew Bomback
Andrew S. Bomback, MD, MPH, is a nephrologist who specializes in glomerular diseases and resistant hypertension. Dr. Bomback received his undergraduate degree from Harvard University and his medical degree from Columbia University College of Physicians and Surgeons. He completed residency in Internal Medicine and fellowships in Nephrology and Clinical Epidemiology at the University of North Carolina at Chapel Hill, where he was the Doc J. Thurston III Fellow in Nephrology and Hypertension. In 2009, he returned to Columbia University as an associate at the Center for Glomerular Diseases and is currently Assistant Professor of Medicine at Columbia University Medical Center. Dr. Bomback is a member of the ColumbiaDoctors Hypertension Center, a multi-disciplinary center of excellence that provides high quality care and state-of-the-art diagnostic testing for patients with hypertension,
Dr. Bomback has published over 100 peer-reviewed articles and book chapters on the subjects of chronic kidney disease, glomerular diseases, and hypertension. He is the co-author of the textbook, Chronic Kidney Disease and Hypertension Essentials, and an editor of the National Kidney Foundation's Primer on Kidney Diseases. He is the recipient of the 2013 Daniel V. Kimberg Junior Faculty Award for oustanding teaching of medical students and housestaff.
Dr. Bomback's research interests focus on evaluating novel therapies for glomerular diseases. He currently serves as principal or co-investigator on clinical trials of new treatments for IgA nephropathy, membranous nephropathy, lupus glomerulonephritis, hereditary nephritis, C3 glomerulopathy, and focal segmental glomerulosclerosis.
Academic Titles
- Assistant Professor of Medicine at CUMC
Administrative Positions
- Director of Clinical Research, Division of Nephrology
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Gender
- Male
Insurance Accepted
Aetna
- EPO
- HMO
- Medicare Managed Care
- NYP Employee Plan
- NY Signature
- POS
- PPO
- Signature Administrators
- Student Health
Affinity
- Essential Plan
- Medicaid Managed Care
AgeWell
- Medicare Managed Care
- Special Needs Plan
Amida Care
- Special Needs Plan
Capital District Physician Health Plan
- Capital District Physician Health Plan
Cigna
- EPO
- Great West
- HMO
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicaid Managed Care
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross Blue Shield
- EPO
- Medicare Managed Care
- PPO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
Fidelis Care
- Child/Family Health Plus
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicaid Managed Care
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare
- MagnaCare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
Oxford Health Plans
- Freedom
- Liberty
UnitedHealthcare
- Columbia University Employee Plan
- Compass (Exchange)
- HMO
- Medicaid (Community Plan)
- Medicare Managed Care
- POS
- PPO
VNSNY CHOICE
- Medicare Managed Care
- SelectHealth
- Special Needs Plan
WellCare
- Medicaid Managed Care
- Medicare Managed Care
*Please contact the provider’s office directly to verify that your particular insurance is accepted.
Contact & Locations
Room 202
New York, New York 10032
Research
Kidney Precision Medicine Project
CURE GN (Cure Glomerulonephropathy) Network
NEPTUNE (Nephrotic syndrome study network)
Ongoing clinical trials in IgA nephropathy (atacicept, ACTH), membranous nephropathy (rituximab), C3 glomerulopathy (CCX168, ACH-4471), FSGS (abatacept, ACTH), and Alport syndrome (bardoxolone).
Research Interests
- Novel therapies for glomerular diseases
- Obesity/metabolic syndrome
- Role of aldosterone in chronic kidney disease
Grants
THE COLUMBIA PCC FOR CUREGN: THE CURE GLOMERULONEPHROPATHY NETWORK (Federal Gov)
Jun 1 2019 - Jun 30 2024
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AVACOPAN (CCX168) IN PATIENTS WITH C3 GLOMERULOPATHY (P&S Industry Clinical Trial)
Jul 19 2017 - Jul 19 2022
KIDNEY PRECISION MEDICINE PROGRAM (KPMP): COLUMBIA AKI RECRUITMENTSITE (Federal Gov)
Sep 15 2017 - Jun 30 2022
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCX168 (AVACOPAN) IN PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS TREATED CONCOMITANTLY WITH RITUXIMAB OR (P&S Industry Clinical Trial)
Apr 25 2017 - Apr 25 2022
IMMUNE TOLERANCE NETWORK EFFICACY OF BELIMUMAB AND RITUXIMAB COMPARED TO RITUXIMAB ALONE FOR THE TREATMENT OF PRIMARY MEMBRANOUS NEPHROPATHY (Federal Gov)
Feb 1 2019 - Jan 31 2021
ANCESTRY, GENETIC RISK AND HEALTH DISPARITIES IN IMMUNE-MEDIATED NEPHRITIS (Federal Gov)
Jul 10 2014 - Apr 30 2020
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, DOSE ASSESSMENT PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCX168 IN SUBJECTS WITH ANTI- NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS (P&S Industry Clinical Trial)
Nov 26 2014 - Nov 26 2019
KIDNEY PRECISION MEDICINE PROGRAM (KPMP): COLUMBIA AKI RECRUITMENTSITE (Federal Gov)
Sep 15 2017 - Jun 30 2019
ADVANCING CLINICAL RESEARCH IN PRIMARY GLOMERULAR DISEASES (Federal Gov)
Sep 16 2013 - May 31 2019
ANCESTRY, GENETIC RISK AND HEALTH DISPARITIES IN GLOMERULAR DISEASES (Federal Gov)
Jul 10 2014 - Apr 30 2019
ANCESTRY, GENETIC RISK AND HEALTH DISPARITIES IN GLOMERULAR DISEASES (Federal Gov)
Jul 10 2014 - Apr 30 2019
ANCESTRY, GENETIC RISK AND HEALTH DISPARITIES IN GLOMERULAR DISEASES (Federal Gov)
Jul 10 2014 - Apr 30 2019
ADVANCING CLINICAL RESEARCH IN PRIMARY GLOMERULAR DISEASES (UM1) (Federal Gov)
Sep 16 2013 - May 31 2018
ADVANCING CLINICAL RESEARCH IN PRIMARY GLOMERULAR DISEASES (UM1) (Federal Gov)
Sep 16 2013 - May 31 2018
ADVANCING CLINICAL RESEARCH IN PRIMARY GLOMERULAR DISEASES (Federal Gov)
Sep 16 2013 - May 31 2018
LUPUS NEPHRITIS BIOMARKER STUDY: BASELINE CHARACTERISTICS OF PATIENTS (Private)
Jan 1 2011 - Dec 31 2013
LUPUS NEPHRITIS BIOMARKER STUDY: BASELINE CHARACTERISTICS OF PATIENTS (Private)
Jan 1 2011 - Dec 31 2012
Selected Publications
- Bomback AS, Muskala P, Bald E, Chwatko G, Nowicki M (2009) Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage Clin Nephrol 72(6):449-456
- Bomback AS, Kshirsagar AV, Whaley-Connell AT, Chen SC, Li S, Klemmer PJ, McCullough PA, Bakris GL (2010) Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP) Am J Kidney Dis 55(3 Suppl 2):S4-S14
- Bomback AS, Derebail VK, Shoham DA, Anderson CA, Steffen LM, Rosamond WD, Kshirsagar AV (2010) Sugar-sweetened soda consumption, hyperuricemia, and kidney disease Kidney Int 77(7):609-616
- Bomback AS, Appel GB (2010) Updates on the treatment of lupus nephritis J Am Soc Nephrol 21(12):2028-2035
- Bomback AS, Rekhtman Y, Whaley-Connell AT, Kshirsagar AV, Sowers JR, Chen SC, Li S, Chinnaiyan KM, Bakris GL, McCullough PA (2010) Gestational diabetes mellitus alone in the absence of subsequent diabetes is associated with microalbuminuria: results from the Kidney Early Evaluation Program (KEEP) Diabetes Care 33(12):2586-2591
- Bomback AS, Song H, D'Agati VD, Cohen SD, Neal A, Appel GB, Rovin BH (2010) A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy Nephrol Dial Transplant 25:3442-3446
- Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B, D'Agati VD, Markowitz GS (2011) ANCA-associated glomerulonephritis in the very elderly Kidney Int 79(7):757-764
- Bomback AS, Herlitz LC, Markowitz GS (2012) Renal biopsy in the elderly and very elderly: useful or not? Adv Chronic Kidney Dis 19(2):61-67
- Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB (2012) Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis Clin J Am Soc Nephrol 7(5):748-756
- Bomback AS, Canetta PA, Beck Jr LH, Ayalon R, Radhakrishnan J, Appel GB (2012) Treatment of Resistant Glomerular Diseases with Adrenocorticotropic Hormone Gel: A Prospective Trial Am J Nephrol 36(1):58-67
For a complete list of publications, please visit PubMed.gov